Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Oruka Therapeutics (ORKA), Merck & Company (MRK)

Tipranks - Tipranks - Fri Apr 10, 6:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oruka Therapeutics (ORKA) and Merck & Company (MRK) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Oruka Therapeutics (ORKA)

In a report released today, Yatin Suneja from Guggenheim reiterated a Buy rating on Oruka Therapeutics, with a price target of $125.00. The company’s shares closed last Wednesday at $62.01.

According to TipRanks.com, Suneja is a 5-star analyst with an average return of 29.1% and a 56.5% success rate. Suneja covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oruka Therapeutics with a $71.33 average price target, a 14.2% upside from current levels. In a report issued on April 6, UBS also assigned a Buy rating to the stock with a $75.00 price target.

See the top stocks recommended by analysts >>

Merck & Company (MRK)

Guggenheim analyst Vamil Divan maintained a Buy rating on Merck & Company yesterday and set a price target of $140.00. The company’s shares closed last Wednesday at $123.18.

According to TipRanks.com, Divan is a 5-star analyst with an average return of 9.8% and a 56.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Eledon Pharmaceuticals, and Travere Therapeutics. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $133.35, which is an 11.5% upside from current levels. In a report issued on March 24, BMO Capital also maintained a Buy rating on the stock with a $135.00 price target.

Read More on ORKA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).